Lung cancer is the second most common cancer in the world. In the U.S. alone, more than 200,000 patients are diagnosed with this asymptomatic disease every year – and often far too late, leading to relatively low chances of survival.1 Regular lung cancer screenings enable physicians to detect tumors at earlier stages during which minimally invasive surgery might be more appropriate. However, when the lesions are small and deep, treatment using conventional two-room workflows can be challenging.2 This is because CT-based needle localization in the interventional suite followed by transfer to the OR involves risks such as needle dislocation, pneumothorax in an environment less safe than the OR itself,3 and patient anxiety during waiting times.
Our imaging systems with syngo software applications allow you to move ahead by expanding precision medicine in the treatment of lung cancer. Bringing CT-like imaging directly to the OR, ARTIS pheno can visualize even small lesions and distal airways as well as provide guidance throughout the procedure.2,4,5 Standardizing treatment for lung cancer to advance therapy outcomes has never been so firmly within reach.
